Zelavespib HCl is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. Zelavespib HCl shows antitumor activity in many preclinical models of malignancy. Zelavespib HCl has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.
Molecular Weight:
548.83
Purity:
98.00%
CAS Number:
[2095432-24-7]
Formula:
C18H22ClIN6O2S
Target:
HSP|||DNA/RNA Synthesis
T6960L
* VAT and and shipping costs not included. Errors and price changes excepted
